Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects on Incidence of Cardiovascular Events of the Addition of Pioglitazone as Compared With a Sulphonylurea in Type 2 Diabetic Patients Inadequately Controlled With Metformin.

Next Previous
Trial Profile

Effects on Incidence of Cardiovascular Events of the Addition of Pioglitazone as Compared With a Sulphonylurea in Type 2 Diabetic Patients Inadequately Controlled With Metformin.

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 17 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pioglitazone (Primary) ; Glibenclamide; Gliclazide; Glimepiride; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions
  • Acronyms TOSCA-IT

Most Recent Events

  • 01 Dec 2012 Recruitment is expected to be complete by June 2013, according to an article published in Diabetes Care. At the time of publication, 2,400 patients had been randomized.
  • 01 Dec 2012 Planned number of patients changed from 5172 to 3371 according to an article published in Diabetes Care and the ClinicalTrials.gov registry record.
  • 01 Dec 2012 Study design and rationale published in Diabetes Care.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top